Scarica l'app Stockscreener
1.50
1.32%
-0.02
Precedente Chiudi:
$1.52
Aprire:
$1.53
Volume 24 ore:
68,890
Relative Volume:
0.37
Capitalizzazione di mercato:
$68.79M
Reddito:
$134.00K
Utile/perdita netta:
$-9.93M
Rapporto P/E:
-4.4118
EPS:
-0.34
Flusso di cassa netto:
$-6.72M
1 W Prestazione:
+44.23%
1M Prestazione:
+2.74%
6M Prestazione:
-22.68%
1 anno Prestazione:
-34.50%
Intervallo 1D:
$1.485
$1.5899
Intervallo di 1 settimana:
$1.07
$1.66
Portata 52W:
$1.00
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
Nome
Entera Bio Ltd
Settore
Industria
Telefono
972-2-532-7151
Indirizzo
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.50 | 69.70M | 134.00K | -9.93M | -6.72M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-22 | Iniziato | Aegis Capital | Buy |
Entera Bio Ltd Borsa (ENTX) Ultime notizie
Is Entera Bio Ltd. stock risky to hold nowWeekly Investment Summary & Growth Oriented Trading Recommendations - mfd.ru
Aug Momentum: Can Entera Bio Ltd deliver consistent dividendsEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - GlobeNewswire Inc.
Why Entera Bio Ltd. stock could rally in 2025Chart Signals & Expert Approved Momentum Trade Ideas - mfd.ru
Will Entera Bio Ltd. stock gain from government policiesJuly 2025 Sentiment & High Conviction Investment Ideas - mfd.ru
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead - Asianet Newsable
Insider Buying: Steven Rubin Acquires Shares of Entera Bio Ltd (ENTX) - GuruFocus
Sean Ellis Buys 18,000 Shares of Entera Bio (NASDAQ:ENTX) Stock - MarketBeat
Insider Buying: Entera Bio (NASDAQ:ENTX) Director Buys 10,000 Shares of Stock - MarketBeat
Entera Bio Shares Rise After Open Market Purchase By Board Members - Nasdaq
Entera Bio Ltd. Board Members and CEO Purchase Company Shares Amid Ongoing Development of Oral Therapies - Quiver Quantitative
Entera Bio insiders are buying more of their own shares on market - Stock Titan
Why Entera Bio Ltd. (5DT) stock is favored by hedge funds2025 Investor Takeaways & Accurate Trade Setup Notifications - mfd.ru
Entera Bio appoints Geno Germano as board chairman By Investing.com - Investing.com South Africa
Entera Bio appoints former Pfizer executive Geno J. Germano as chairman of the board ahead of key milestones - marketscreener.com
Entera Bio Ltd: Geno J. Germano appointed as chairman of Entera Bio - marketscreener.com
Entera Bio Ltd. Announces Board Changes - marketscreener.com
Entera Bio Attracts Former Pfizer Group President as It Enters a New Phase (NASDAQ: ENTX) - GuruFocus
Entera Bio appoints Geno Germano as board chairman - Investing.com
Entera Bio Names Geno Germano Independent Board Chairman - The Globe and Mail
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones - The Manila Times
Entera Bio Ltd. Appoints Geno J. Germano as New Chairman of the Board as Company Advances Oral Peptide Pipeline - Quiver Quantitative
Ex-Pfizer exec to lead Entera Bio board as 2026 oral PTH trials planned - Stock Titan
Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Geno J. Germano - Longbridge
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development - Finviz
Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Steven D. Rubin - Longbridge
OPKO and Entera expand collaboration to develop oral PTH treatment By Investing.com - Investing.com Nigeria
Stop Loss: Should I invest in Entera Bio Ltd before earningsJuly 2025 Rallies & Reliable Trade Execution Plans - baoquankhu1.vn
OPKO and Entera expand collaboration to develop oral PTH treatment - Investing.com
Entera Bio Expands OPKO Partnership, Adds New Director - TipRanks
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism - The Manila Times
OPKO Health and Entera Bio expand partnership for oral PTH tablet - StreetInsider
Entera Bio Signs Amended And Restated Collaboration And License Agreement With OPKO - TradingView
Entera Bio Ltd. Announces Board Changes, Effective February 1, 2026 - marketscreener.com
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan
OPKO Health and Entera Bio Expand Partnership to Advance - GlobeNewswire
Breakout Move: Can Entera Bio Ltd weather a recessionJuly 2025 Earnings & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth? - simplywall.st
Contrasting Entera Bio (NASDAQ:ENTX) and Barinthus Biotherapeutics (NASDAQ:BRNS) - Defense World
Is Entera Bio Ltd. on track to beat earnings2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - mfd.ru
Entera Bio Prepares For Key Q1 Milestones As EB613 Nears Phase 3 Transition - RTTNews
Investment Review: Can Launch One Acquisition Corp Debt Equity Composite Units weather a recessionGap Down & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Entera Bio plans FDA submission for osteoporosis drug in Q1 2026 - Investing.com Nigeria
Entera Bio Ltd. Announces Key Milestones and Upcoming FDA Submissions for EB613 and Oral Hypoparathyroidism Programs in Q1 2026 - Quiver Quantitative
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook - Sahm
Entera Bio (NASDAQ:ENTX) Trading Down 3.1%Here's Why - MarketBeat
Aug Levels: Is Entera Bio Ltd still a buy after recent gainsPortfolio Gains Summary & Risk Controlled Daily Plans - baoquankhu1.vn
What margin trends mean for Entera Bio Ltd. stock2025 Fundamental Recap & Community Verified Trade Alerts - Улправда
Will Entera Bio Ltd. stock remain a Wall Street favoriteJuly 2025 Momentum & Technical Confirmation Alerts - Улправда
Is Entera Bio Ltd. stock oversold or undervalued2025 Buyback Activity & Reliable Price Action Trade Plans - Улправда
Is Entera Bio Ltd. (5DT) stock prepared for digital transitionRate Hike & Long-Term Capital Growth Ideas - Улправда
Entera Bio Ltd Azioni (ENTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Entera Bio Ltd Azioni (ENTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ellis Sean | Director |
Feb 09 '26 |
Buy |
1.24 |
18,000 |
22,320 |
178,098 |
| Toledano Miranda Jayne | Chief Executive Officer |
Dec 29 '25 |
Buy |
1.81 |
11,000 |
19,912 |
426,575 |
| LIEBERMAN GERALD M | Director |
Apr 01 '25 |
Option Exercise |
1.00 |
23,952 |
23,952 |
300,160 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):